New strategies in neurological diseases
What it found
No result yet.
What was tested
Treatment tested
- Dalfampridine
Voltage-gated potassium channel blocker
What it measured
Main measures
we expect to find a >21.43% difference between the treatment (baseline/end of treatment T25FT score ratio: mean 1.4, SD 0.17) and the placebo group (baseline/end of treatment T25FT score ratio: mean 1.1, SD 0.04).
Other measures (1)
changes of motor control and learning (saccades adaptation, gait analysis, ICARS, Ashworth score for spasticity, a lower extremity manual muscle test -LEMMT); Changes of fatigue (ocular motor fatigue task, Fatigue Severity Scale - FSS); Changes of functional disability and quality of life (12-item multiple sclerosis walking scale MSWS-12, Activities of Daily Living - ADL, Barthel index - BI, Funct
Thinking and memoryFatigueWalking and mobilityNerve conduction testsSpasticityQuality of life (reported by participants)
Who could take part
MS (type not specified)
Exclusion: Onset of multiple sclerosis exacerbation within 90 days of screening,
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To evaluate the safety and clinical effectiveness of cerebellar TBS and 4-aminopiridine for enhancing the effects of gait rehabilitation
Loading reviews and guidelines…
Related trials
- AmpPT
Phase 3 · Recruiting
Still running
- RESTORE
Phase 3 · Stopped early
Stopped: not working
- MUST
Not a drug-phase study · Completed
Result in a paper, not read yet
- FAMILY
Completed
Result in a paper, not read yet
- Fampridine Study in Activities of Daily Living
Phase 4 · Completed
No result found
- Fampridine Pregnancy Exposure Registry
Stopped early
Stopped early
History
Started
Nov 2020
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error